Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 10,10 € (+282,58%). Mediana wynosi 10,10 € (+282,58%).
| Kupuj |
12 |
| Trzymaj |
1 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
X4 Pharmaceuticals reduces sample size of 4WARD phase III study and streamlines market‑launch plan
X4 Pharmaceuticals lowered the recruitment target for the 4WARD phase III study to 126 patients after consulting with the FDA and says this retains 88% power for the infection‑rate endpoint and 93% for the ANC endpoint. Recruitment is now in the triple digits and accelerated after the switch to Parexel, and the company expects study completion and top‑line data in early 2026. X4 plans a US commercial model with 50–60 field sales representatives, is preparing a G‑CSF titration study to boost physician uptake, and considers funding through 2029 sufficient for the next steps. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 7,72 mln | 360,94% |
| Zysk brutto | 6,3 mln | 401,99% |
| Zysk netto | -14,16 mln | 35,18% |
| EBITDA | -11,19 mln | 42,91% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 248,41 mln € |
Liczba akcji | 94,32 mln |
Maksimum/minimum z 52 tygodni | 4,24 € - 2,46 € |
| Dywidendy | Nie |
Beta | 0,35 |
C/Z (PE Ratio) | -2,50 |
PEG (PEG Ratio) | -0,01 |
C/WK (PB Ratio) | 2,44 |
C/S (PS Ratio) | 17,86 |
Profil spółki
| Nazwa | X4 PHARMACEUTICALS INC |
| CEO | Adam R. Craig |
| Pracownicy | 45 |
